• MORE MARKET STATS

Viveka Roychowdhury

Articles By Viveka Roychowdhury

111 Articles

Finding the hidden gems

Vishal Jajodia could sign up as a poster boy for Prime Minister Narendra Modi's Make In India campaign

Finding the hidden gems

Balancing the scales

Besides the balanced reasoning within the Delhi HC judgement, it is the SC's intervention which could see this case go down as a major milestone

Balancing the scales

TC Biopharm to start phase II/III studies of ImmuniCell in October

Currently focused on skin, renal and lung cancer, the platform has potential to treat all types of cancer tumours as well as viral infections like HIV, Ebola and severe influenza. Viveka Roychowdhury reports

TC Biopharm to start phase II/III studies of ImmuniCell in October

The Journey From Cow to Consumption

Post Diwali, ColoPlus sachets will be launched in India, thanks to a collaboration between ColoPlus and the Rs 1,450 crore Pune-based Parag Milk Foods. Viveka Roychowdhury speaks to Conny Hagman, Chief Executive Officer, Colo

The Journey From Cow to Consumption

Mainstreaming AYUSH

The last month saw a major milestone in the patent versus patient debate

Mainstreaming AYUSH

The tipping point?

The ongoing dengue infection has become fodder for the political mill in Delhi and while we all mourn the loss of lives, there is hope that at least now, the centre and state health functionaries will be forced to cooperate a

The tipping point?

The journey from cow to consumption

What does it take to transform bovine colostrum into a nutritional supplement, ensuring that all the immunoglobins, vitamins and other nutrients are preserved from cow to consumption? After years of research, Sweden-based Col

The journey from cow to consumption

Playing for high stakes

According to the latest data from the India Brand Equity Foundation (IBEF), the Indian domestic pharma market ended FY15 with a growth of 12 per cent, touching Rs 90,400 crores ($ 15 billion)

Playing for high stakes

The rockstar of cardiac care

Authors of a recent study published in PLoS ONE questioned the use of two commonly prescribed presurgical tests in the US

The rockstar of cardiac care

Mylan’s One Quality Standard a long way off

Some industry observers are surprised that ‘significant violations’ of this nature have not warranted an import alert or ban

Mylan’s One Quality Standard a long way off

Getting the science right

The ‘no pain, no gain’ mantra seems to be finally putting the $25 billion AstraZeneca on the road to recovery, as it continues to prune sites and sell off once prized R&D assets to finance the promising leads entering pha

Getting the science right

New strategies for growth

After a decade of pain, there are some reassuring signs that the pharmaceutical industry may just be seeing the faint glimmers of light at the end of the R&D pipeline

New strategies for growth

‘We want to be relevant to the Indian market’

Kimberly-Clark spun off its healthcare business to create a new entity, Halyard Health in order to sharpen its focus on the healthcare sector. As an emerging market, India has been identified as one of the key growth drivers

‘We want to be relevant to the Indian market’

Should docs fear online pharmacies?

The Indian Medical Association (IMA) recently released a white paper detailing why the Indian government should not allow online pharmacies

Should docs fear online pharmacies?

Digital India: A new game needs new rules

With the launch of the Digital India campaign in early July, it is time to relook India Pharma Inc’s engagement with technology

Digital India: A new game needs new rules

Cleanroom tech to go more hi tech

Cleanrooms are perhaps one of the most crucial parts of the lifesciences sector, given that regulatory agencies are upping the ante when it comes to monitoring good manufacturing practices (GMP)

Cleanroom tech to go more hi tech

BI’s afatinib LUX-Lung 8 trial data released at ASCO 2015

Patients from 23 countries, including India, participated in the trial, which is reportedly the first prospective trial to directly compare two different TKIs, afatinib and erlotinib By Viveka Roychowdhury

BI’s afatinib LUX-Lung 8 trial data released at ASCO 2015

Lee Pharma revives the CL debate

With little known Lee Pharma filing India's third compulsory licensing (CL), legal eagles and everyone interested or connected to pharmaceutical IP are gearing up for yet another discussion on this topic

Lee Pharma revives the CL debate

Physician, heal thyself

July 1 was designated as Doctor's Day by the Government of India in 1991 to honour the memory of Dr Bidhan Chandra Roy, a legendary who also became the second chief minister of West Bengal

Physician, heal thyself

TRIPs-ing time again

When governments have to weigh public health against IP issues, LDCs and developing countries really have no choice but to plug for the former

TRIPs-ing time again

Data integrity … dil se

Two reports, released in early June, have both good news and bad news for the pharma industry in India

Data integrity … dil se

Making a living

The cloak of altruism does not quite fit the blood transfusion value chain in this country

Making a living

2015 USTR Special 301 Report Reactions and the way forward

In the aftermath of this year’s USTR Special 301 Report, which retained India on the Priority Watch List, industry leaders comment on the Report’s result, as well as the overall IPR scenario in India. By Viveka Roychowdhu

2015 USTR Special 301 Report Reactions and the way forward

Boosting APIs and exports take top priority at 3rd iPhex 2015

Govt officials promote India as ‘Healthcare provider to the world’

Boosting APIs and exports take top priority at 3rd iPhex 2015

When patience is not a virtue

India once again made it to the Priority Watch list of the 2015 USTR Special 301 Report, but this year, the reaction from India’s pharma industry was more measured

When patience is not a virtue

Rage of India’s nursing angels

On one hand, doctors and nurses employed in the National Health Mission (NHM) were forced to go on strike to demand the same wages as other health centre employees

Rage of India’s nursing angels

Rebooting Jan Aushadhi

As Prime Minister Modi completes a year in office this May, there will no doubt be many lists of this government’s achievements and comparison with the previous administration

Rebooting Jan Aushadhi
Advertisement
Income Tax Calculator, Budget 2019, How to Calculate Income Tax

 

Stock Market

Advertisement
Advertisement